MAY 16, 2017 7:32 PM PDT

On-the-Go T Cells Better Equipped to Kill Tumor Cells

WRITTEN BY: Kara Marker

The main idea behind immunotherapy as an anticancer approach is to equip the human immune system with the tools it needs to fight cancer on its own, and enhancing the body’s natural strategies is often an effective method. Recently, scientists from the Garvan Institute of Medical Research found another natural strategy to improve on: T cell migration from tumor to tumor.

Cells that have exited from a tumor (red) in a lymph node of a photoconvertible mouse model. Credit: Tatyana Chtanova

There are so many types of cancer that sometimes a cure or complete prevention plan seems beyond our reach. However, what the many types of cancer have in common is what almost always ultimately causes death in cancer patients: metastasis. If T cells can be be trained to follow the tumor even as it metastasizes to different tissues in the body, cancer, even late-stage cancer, wouldn’t seem so daunting.

"We know that T cells and other immune cells accumulate inside tumors, but until now we've known very little about what happens next. How does the environment within the tumor change the cells? Do they leave the tumor? Which types of immune cells leave? Where do they go, and why?" asked lead research Dr. Tatyana Chtanova.

Chtanova and the team from the Garvan Institute used a strategy called “photoconversion” to observe the movement of T cells during an anticancer attack. Mouse cells were labeled with a green fluorescent compound that makes them appear red when researchers shine light on a tumor, indicating which cells made the journey into the tumor and which did not.

"We saw immune cells leaving the tumour and moving into lymph nodes - and, importantly, we could see immune cells moving out of one tumour and into another, distant tumour,” Chtanova described.

Interestingly, the types of cells going in and the cells going out were different. T cells were more likely than other cells to leave a tumor and travel to either the lymph nodes or another tumor site, specifically CD8+ effector T cells. This makes sense, Chtanova says, because these T cell subtypes “promote tumor destruction.”

Their second observation is all the more promising: T cells leaving the tumor to travel somewhere else were more activated, with “stronger cytotoxic activity” compared to the cells that stayed put.

"Within the tumor, these T cells are acquiring knowledge about the cancer that helps them to seek and destroy tumor cells,” Chtanova explained. “It's possible that these T cells 'on patrol' are using their new-found knowledge to attack cancerous cells in the second tumor."

The next logical step is this: if effector T cells leaving the tumor to fight cancer elsewhere are better at killing tumor cells, there should be a way to maximize the number of T cells traveling to multiple destinations in the body.

The present study was published in the journal Proceedings of the National Academy of Sciences (PNAS).

Source: Garvan Institute of Medical Research

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 10, 2020
Neuroscience
Nanoparticles Pass the Blood-Brain Barrier in Zebrafish
NOV 10, 2020
Nanoparticles Pass the Blood-Brain Barrier in Zebrafish
Video:  Explains the challenges of delivering medicine to the brain, and possibly tools to pass the blood-brain bar ...
DEC 02, 2020
Immunology
A Shingles Vaccine for Cancer Patients
DEC 02, 2020
A Shingles Vaccine for Cancer Patients
Receiving a vaccine (usually in the form of an inactivated pathogen) triggers an immune response without the symptoms of ...
DEC 23, 2020
Immunology
COVID Survivors Stay Immune for at Least a Year
DEC 23, 2020
COVID Survivors Stay Immune for at Least a Year
Once the coronavirus enters the body, the immune system springs into action, producing antibodies that bind to and neutr ...
JAN 28, 2021
Immunology
Killers With a Hit on the Spike
JAN 28, 2021
Killers With a Hit on the Spike
Natural killer cells, or NK cells, are specialized immune cells of the innate immune system. Their job revolves around e ...
FEB 03, 2021
Clinical & Molecular DX
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
FEB 03, 2021
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
Rheumatoid arthritis, or RA, is a painful and debilitating autoimmune disorder of the joints, particularly those of the ...
Loading Comments...